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Abstract
The importance of genetic mutations in carcinogenesis
has been recognized, and it has been proposed that
aberrant mutation of mRNA may represent a novel
oncogenic principle. Here we report that the mRNA of a
homeobox gene prox1, a candidate tumor suppressor,
suffers adenosine-to-inosine nucleotide conversion
and loses tumor-suppressive functions in a subset of
human cancers. Expression of Prox1 was reduced in
pancreatic cancers, and the extent of reduction corre-
lated with progression of tumor differentiation. A-to-G
base change was found in prox1 cDNA taken from
human cancer cells, but not in corresponding genomic
DNA. We mapped four common mutation sites in prox1
gene, and the same four sites were mutated in human
clinical samples from several cancers. Tetracycline-
induced wild-type (wt) Prox1 in tumor cells inhibited
transforming activity and cellular proliferation. How-
ever, mutant Prox1 with the four common sites altered
from A to G lost these inhibitory functions. In mice,
xenografts of tumor cells with tetracycline-induced wt-
Prox1 formed tumor masses significantly more slowly
than control tumors, whereas mutated Prox1 had no
effect. These findings may point to a pivotal role of the
RNA mutation of prox1 gene in the pathogenesis of
human cancer progression.
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Introduction
Cancer is essentially a genetic disease of somatic cells [1].
According to the currently accepted model of carcino-
genesis, a series of mutations in coding regions of onco-
genes or tumor-suppressor genes is required for cancer
development. In the model, genomic DNA sequence with
mutations is transcribed to mRNA that is finally translated
into a functionally aberrant protein, leading to deregulation
of fundamental cellular processes. Besides genetic mu-
tations, several epigenetic events, such as methylation of
promoters and histone acetylation, are known to affect
targeted gene expression and, thus, to quantitatively modify
the level of functional proteins [2]. In all these scenarios, mRNA
is viewed as an intermediate between DNA and protein [3].
However, it has been recently revealed that mRNA is actively
regulated by a variety of machineries playing roles at the level of
mRNA processing, mRNA stabilization, and gene transcription,
such as nonsense-mediated decay (NMD), RNA interference,
and RNA mutation, as well as alternative splicing. Recent re-
ports suggest that functional deregulation of these RNA-based
mechanisms may be involved in carcinogenesis. NMD is
shown to degrade BRCA1 mRNA bearing nonsense mutations
[4]. Ras genes contain multiple binding sites for the let-7 family
of microRNA, and the expression of let-7 and Ras is inversely
correlated in human lung cancers [5].
The homeobox gene prox1 is related to the Drosophila
prospero gene, which mediates cell fate decisions of neuro-
blasts [6]. Analysis of Prox1-deficient mice indicated its various
role in lens fiber elongation, hepatocytemigration, development
of lymphatic vessels, retinal cell differentiation, and pancreatic
development. In pancreatic development, lack of Prox1 activity
disrupts epithelial pancreatic morphology, hinders pancreatic
growth before E11.5, and decreases the formation of islet cell
precursors after E13.5 [7]. Prox1 is considered to contribute to
the allocation of an adequate supply of islet cells throughout
pancreatic ontogeny by preventing exocrine cell differentiation
of multipotent pancreatic progenitors, whereas the role of Prox1
in the pancreas of adults remains unknown. Prox1 is also re-
quired for the proliferation and migration of hepatoblasts in
liver development [8]. However, cells lacking Prox1 are less
likely to stop dividing, and ectopic expression of Prox1 forces
progenitor cells to exit the cell cycle in the retina [9] and causes
abnormal cellular proliferation by a downregulated expression
of cell cycle inhibitors in lens fibers [10]. The role of Prox1 is very
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multifunctional, and its physiological functions may change
according to developmental stage, organ, or type of cancer.
We have recently reported that there is a significant
correlation between Prox1 expression and the differentiation
scores of hepatocellular carcinoma (HCC) [11]. Low expres-
sion of Prox1 in tumors is closely associated with poor
prognosis. Specific knockdown of prox1 by RNA interference
strongly accelerates in vitro cell growth, whereas overexpres-
sion of Prox1 greatly suppresses growth. These results
suggest that Prox1 is involved in the differentiation and
progression of HCC and, thus, may be a candidate tumor-
suppressor gene for HCC.
In this study, we report our finding that prox1 suffers
adenosine-to-inosine (A-to-I) RNA mutation without genomic
mutation in a subset of human cancer cells. RNA mutation is
a mechanism capable of changing genetic information with-
out affecting genomic DNA. A-to-I nucleotide conversion
might change the coding potential of mRNA and might result
in the synthesis of an isoform of the protein, which is not
predictable from unaffected genomic DNA. Analyzing the
effect of RNA mutation on protein function, we found that
wild-type (wt) Prox1 suppressed tumor cell proliferation
in vitro and in vivo, and that the mutant form of Prox1 lost
its suppressive effect. prox1 genomic mutation and methyl-
ation have been identified in hematologic cell lines [12], and
our study suggests that RNA mutation, as a new mechanism
of tumorigenesis, may induce or alter tumor progression.
Materials and Methods
Cells and cDNA Libraries
Miapaca2 and Panc1 are human pancreatic cancer cell
lines with relatively poor differentiation, HCT116 is a human
colon cancer cell line, and human embryonic kidney 293 cells
are used as controls. All four cell lines were cultured in
DMEM supplemented with 10% fetal calf serum (JRH Bio-
sciences, Lenexa, KS). Human cDNA libraries of the brain,
cerebellum, lung, heart, esophagus, small intestine, colon,
liver, pancreas, spleen, kidney, testis, and ovary were pur-
chased from Biochain Institute (Hayward, CA).
Patient Samples
Sixty paraffin-embedded formalin-fixed tissues of pancre-
atic cancers were retrieved from the 2000 to 2004 surgical
pathology files of Kyoto University Hospital (Kyoto, Japan).
Frozen surgical tissue samples from 9 cases of esophageal
cancer, 24 cases of pancreatic cancer, and 5 cases of colon
cancer were obtained for the preparation of total RNA and
genomic DNA. Total RNA and genomic DNA were isolated
sequentially using ISOGEN (Nippon Gene, Tokyo, Japan)
according to the manufacturer’s instructions. All samples
were obtained with informed consent, and their use was
approved by the ethics committee of the hospital.
Immunohistochemistry
Paraffin-embedded sections were deparaffinized and hy-
drated by standard methods. After antigen retrieval with
microwave (600 W for 5 minutes; 200 W for 10 minutes) in
sodium citrate, endogenous peroxidase was quenched
with 3% H2O2 in methanol for 10 minutes. The sections
were placed in TNB buffer (TSA Biotin System kit/NEL700;
Perkin Elmer Life Science, Wellesley, MA) for 30 minutes
to block nonspecific hybridization, after which they were
exposed to 1:100 rabbit anti-Prox1 antibody (ReliaTech
GmbH, Braunschweig, Germany) in TNB for 16 hours at
4jC, washed with TNT buffer, and incubated for 30 minutes
at room temperature with biotinylated secondary antibodies
(Dako, Carpinteria, CA) diluted in TNB. Tyramide signal am-
plification was used to enhance staining. Peroxidase activity
was developed with EnVision kit/HRP (DAB; Dako), and
sections were counterstained with hematoxylin. In negative
control stains, primary antibodies were omitted. Staining
intensity was estimated for each cell type on a three-step
scale (, +, and ++) by three investigators.
Genomic DNA and RNA Isolation, and Reverse
Transcription–Polymerase Chain Reaction (RT-PCR)
Genomic DNA were isolated using QIAamp DNA Mini
Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Total RNA from cultured cell lines was isolated
with TRIzol Reagent (Gibco BRL, Grand Island, NY), sub-
sequently digested with RNase-free DNase I (Roche, India-
napolis, IN), and tested for integrity. Ten micrograms of total
RNA was used to synthesize cDNA by using SuperScript II
reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo-dT
primers. Four sets of PCR primers intended to cover the en-
tire coding region of prox1 gene were used for sequencing.
Primer sequences were as follows: set 1, 5V-ATGCCTG-
ACCATGACAGCAC-3V (forward) and 5V-TTTCATTGCCCC-
TTAATGCC-3V (reverse); set 2, 5V-TAATTCGGGGTATGAG-
CCAT-3V (forward) and 5V-TCTGGCCTGGGGGATCTG-3V
(reverse); set 3, 5V-CAGGTTCCTCAGGTCTTC-3V (forward)
and 5V-CTTCCTGCATTGCACTTCC-3V (reverse); set 4, 5V-
CATCTCACCACCTGAGCC-3V (forward) and 5V-CTACTCA-
TGAAGCAGCTCTTG-3V (reverse). PCR conditions were
94jC for 3 minutes, followed by 30 cycles of 94jC for 30 sec-
onds, 60jC for 30 seconds, and 72jC for 1minute; and a final
extension step of 72jC for 7 minutes. For analysis of Prox1
expression, its 3V region was amplified with primers 5V-
CAGATGGAGAAGTACGCAC-3V (forward) and 5V-CTACT-
CATGAAGCAGCTCTTG-3V (reverse) and, as control, glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
was amplified with primers 5V-GACAACAGCCTCAAGA-
TCATCA-3V (forward) and 5V-GGTCCACCACTGAC-
ACGTTG-3V (reverse). Both reactions involved initial dena-
turation at 94jC for 3 minutes, followed by 25 to 30 cycles at
94jC for 30 seconds, 57jC for 30 seconds, and 72jC for
30 seconds (for prox1); or 18 cycles at 94jC for 30 seconds,
58jC for 30 seconds, and 72jC for 30 seconds (for GAPDH),
with a final extension step of 72jC for 7 minutes.
Sequence Analysis
All PCR products were first directly sequenced without
cloning using the ABI PRISM Big Dye Terminator Cycle
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Sequencing Ready Reaction (Applied Biosystems, Foster
City, CA) by ABI PRISM 3100 sequence analyzer (Applied
Biosystems). PCR products were run on 2% agarose gels
and, if a single clear band of the correct approximate size
was obtained, it was excised or purified by QIAquick PCR
purification kit (Qiagen). When PCR products were directly
sequenced, the extent of mutation at each site was deter-
mined with electropherograms from sequencing reactions
to estimate the relative amounts of A and G semiquantita-
tively: () no trace of G; (+) presence of a trace of G but
less than A; (++) trace of G more than A; (+++) no trace of A.
Subsequently, PCR products were cloned using TOPO TA
cloning kits (Invitrogen), and editing efficiency was estimated
by evaluating the sequence of at least 10 clones.
Plasmids, Transfection, and Cell Proliferation
cDNA of wt-prox1 or mutant (mut) prox1 were subcloned
into the mammalian expression vector pcDNA6/TO (tet op-
erator; Invitrogen). Both 293 and Miapaca2 cells expressing
tet repressor were transfected with wt-prox1 or mut-prox1
construct by using Lipofectamine (Gibco BRL) following the
manufacturer’s instructions. Stable clones were obtained by
selecting for blasticidin and zeocin resistance and were further
confirmed to induce wt-prox1 or mut-prox1 expression in the
presence of tetracycline (0.01 mg/ml for 293 cells; 0.2 mg/ml for
Miapaca2 cells). Cell proliferation assays were performed by
cell counts and colony formation assay. For colony formation
assay, 293 cells were seeded into 10-cm culture plates at
5  105 cells/plate, cultured for 10 days in the presence of
tet, and stained with Giemsa solution. Tet-inducible 293/LacZ
or Miapaca2/LacZ cells were used as negative controls.
Transformation Assay
For cell transformation assay, tet-inducible Miapaca2 cells
were seeded into 0.4% top agar layer of 10-cm culture plates
with 0.8% base agar layer at 10,000 cells/plate and cul-
tured for 21 days in the presence of 0.2 mg/ml tet. The cells
were stained with cell stain solution according to the manu-
facturer’s instructions.
In Vivo Study
Mice were injected subcutaneously with tet-inducible Mia-
paca2 cells at 1  107 cells/mouse. They were maintained
under a continuous administration of 0.4 mg/ml doxycycline
(Dox) in drinking water for 7 weeks. Tumor size was mea-
sured weekly using the formula width2  length/2 and was
finally weighed.
Results
Expression of Prox1 Is Downregulated in Human Pancreatic
Cancer and Correlates with Its Differentiation
To test whether Prox1 protein is associated with pancreatic
tumor progression, we evaluated Prox1 expression in 60 can-
cerous pancreatic tissues of various grades by immuno-
staining. Prox1 was expressed exclusively by ductal cells in
normal tissues adjacent to cancerous regions (Figure 1A), and
staining levels were in proportion to the differentiation grades
of cancer cells (Figure 1, B and C). On screening various
types of human cancer cell lines for prox1 expression by
RT-PCR, although the distribution of prox1 expression reported
Figure 1. Expression of Prox1 is downregulated in human pancreatic cancer
and correlates with its differentiation. (A) Immunostaining of normal pancreatic
tissue. Prox1 expression is localized in ductal cells. (B) Immunostaining of
pancreatic cancers of various grades: well-differentiated (well), moderately
differentiated (moderate), and poorly differentiated (poor). (C) Staining inten-
sity for Prox1 was estimated for each cell type. Columns show the relationship
between tumor differentiation level and the average percent staining intensity
for prox1. *P < .05. (D) Expression and mRNA editing of prox1 in diverse types
of human cancer cell lines. RT-PCR analyses of prox1 expression in human
pancreatic cancer cell lines: HeLa and 293 cells (pancreas), human lung
cancer cell line (lung), human HCC (liver), human gastric cancer cell lines
(stomach), human colon cancer cell lines (colon), and other types of human
cancer cell lines (miscellaneous). GAPDH was used as internal control.
RNA Mutation of prox1 in Human Cancer Cells Takahashi et al. 1005
Neoplasia . Vol. 8, No. 12, 2006
previously was restricted, detectable levels were found in most
types of tumor cell lines in various organs: 11, pancreatic
cancer; 3, small cell lung cancer; 4, HCC; 6, gastric cancer; 4,
colon cancer; 2, neuroblastoma; 1, breast cancer (Figure 1D).
prox1 mRNA Mutation in Human Cancer Cells
To investigate mutations in coding regions of prox1, cDNA
obtained from cancer cell lines were amplified by PCR and
sequenced as a population without cloning. We compared
the sequences with the published human genomic se-
quence and found that electropherograms revealed the pres-
ence of an unambiguous trace of guanosine in positions for
which published data clearly indicated the presence of an
adenosine in Panc1, Miapaca2, and HCT116 cells at nucleo-
tide positions 615, 983, 1000, and 1607 (NM002763; CDS
273-2486) (Figure 2). Three of four mutations identified, at
nucleotide positions 983 (E328G), 1000 (R334G), and 1607
(H536R), generate amino acid changes in translation prod-
ucts. The four sites did not correspond with known single-
nucleotide polymorphisms (SNPs) of genomic origin. We
then sequenced matching genomic DNA samples retrieved
from the same tumor cell lines and confirmed that genomic
DNA sequences exhibit only adenosine signals (Figure 2).
The RNA mutations identified are not seen in any cDNA
library and publicly available expressed sequence tags
covering this gene. Finally, we analyzed human cDNA li-
braries obtained from the brain, cerebellum, lung, heart,
esophagus, small intestine, colon, liver, pancreas, spleen,
kidney, testis, and ovary, but found no signs of A-to-G muta-
tion (data not shown).
Characterization of Mutation Sites in prox1 Transcript
To further analyze mutation sites, PCR products were
cloned and at least 10 individual clones were sequenced.
Notably, inosine is recognized by translational apparatus
as guanosine, so that the change of A-to-G in cDNA impli-
cates A-to-I conversion in mRNA. The frequency of A-to-I
mutation was validated for Panc1, Miapaca2, HCT116, and
293 cells. Set 2 primers (see Materials and Methods section)
were used to amplify the region covering the first three muta-
tions (R205R, E328G, and R334G). Comparing cDNA
sequences with the published genomic sequence revealed
a high number of nucleotide discrepancies in three restricted
sites (Figure 3A, left). However, the sequences of cloned
genomic fragments harbored nucleotide mismatches at ran-
dom sites, most probably due to sequencing error (Figure 3A,
center). The number of A-to-G mismatches between the
cDNA sequence and the published genomic sequence is
higher than all the other 11 types of nucleotide discrepancies
(Figure 3A, right). Excess exclusively in the number of A-to-G
discrepancies over other base changes most probably
reflects cases of bona fide A-to-I RNA mutation. The same
results were found in the other mutation (H536R) covered by
set 3 primers (data not shown). Consequently, no A-to-G
conversion was found in 293 cells, whereas four common
mutation sites were found in Panc1, Miapaca2, and HCT116
cells (Figure 3, B and C). All four sites were within the
N-terminal domain of the prox1 gene, which has not yet been
well characterized (Figure 3B), but interestingly, adenosine
residues at these positions are all conserved in a number of
prox1 homologues from different species (data not shown).
Common multiple base changes within a stretch of several
hundred nucleotides, all being of the A-to-G type, are not
likely accounted for by SNPs or sequencing errors. They are
flanked by evolutionarily conserved regions, and these
nucleotides may have been passed on to all descendants in
the course of evolution because they were somehow impor-
tant for the function of protein products.
Frequency of the RNA Mutation of prox1 in Cancer Cell
Lines and Clinical Samples
The overall frequency of mutation in Panc1, Miapaca2,
and HCT116 cells was 46%, 56%, and 62%, respectively, as
evaluated from cloned sequences, whereas the mutation
Figure 2. Matching genomic DNA and cDNA sequences for Miapaca2 cells. The mutated site is characterized by a trace of guanosine in cDNA sequence, where
genomic DNA sequence exhibits only adenosine signals (indicated by arrows).
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levels of other cancer cells were negative, as evaluated
semiquantitatively by electropherograms (data not shown).
A-to-G base changewas not found in corresponding genomic
DNA from any of the clones sequenced. Furthermore, we
found that the same four sites mutated in human clinical
samples taken from pancreatic, esophageal, and colon
cancers (Table 1). RNA mutation events were observed in
four of nine cases of esophageal cancers (44%), although the
frequency ofmutation in each case varied. A-to-G conversion
was also identified in 2 of 24 cases of pancreatic cancer (8%)
and in 2 of 5 cases of colon cancer (40%).
Prox1 Functions as Tumor Suppressor, and Mutated
Prox1 Loses Its Function In Vitro
To explore the impact of RNAmutations on tumorigenesis,
we expressed wt-Prox1 or mut-Prox1 with the four common
sitesmutated in 293 andMiapaca2 cells using the tet-on gene
expression system and then assessed cellular behavior.
We found, by transformation assay, that the suppression
of colony formation in soft agar by tetracycline-induced
wt-Prox1was evident inMiapaca2 cells (Figure 4A). wt-Prox1
in both 293 and Miapaca2 cells also inhibited cell prolifera-
tion (Figure 4B). However, overexpression of mut-Prox1 lost
these suppressive functions (Figure 4, A and B).
Prox1, But Not mut-Prox1, Suppresses the Growth
of Xenografted Tumors in Mice
To investigate Prox1’s suppressive effect on tumor for-
mation and the loss of function by mutation, we grafted tet-
inducible derivatives ofMiapaca2 cells (wt-Prox1,mut-Prox1,
and LacZ) subcutaneously at both sides of the back of nude
mice (Figure 5A, left). wt-Prox1–overexpressing tumors in
mice treated with Dox grew more slowly than both LacZ
controls inmicewith Dox andwt-Prox1 tumors inmicewithout
Dox (Figure 5). However, mut-Prox1 tumors in mice treated
with Dox completely lost their suppressive activity on tumor-
igenesis (Figure 5B).
Discussion
Based on discrepancies between mRNA (cDNA) and ge-
nomic sequences, we have identified RNA mutations of a
novel candidate tumor-suppressor gene prox1 in a subset
of human cancer cells. wt-Prox1 suppressed tumor cell
Figure 3. Characterization of mutation sites in prox1. (A) Evaluation of the sequences of cloned PCR products for the prox1 gene by set 2 primers (see Materials
and Methods section) from Panc1, Miapaca2, and HCT116 cells. The number of nucleotide discrepancies between published human genomic sequences and the
sequences of cloned PCR products of cDNA (left) or genomic DNA (center) obtained from Panc1, Miapaca2, and HCT116 cells. Distribution of mismatches
between cDNA sequences and published genomic sequences (right). (B) Schematic view of prox1 gene with predicted mutation sites (indicated by arrows) in the
coding region (box: exon). (C) Sequences of individually cloned fragments were aligned to the published human genomic sequence. Mutations identified are
indicated in red.
Table 1. The Frequency of A-to-I RNA Mutation in cDNA and Genomic DNA
Obtained from Human Samples of Pancreatic, Esophageal, and Colon
Cancers.
Patient Number cDNA Genomic DNA
Pancreatic cancer
5 50% (2/4) 0% (0/4)
24 100% (4/4) 0% (0/4)
Esophageal cancer
5 29% (4/14) 0% (0/7)
6 30% (10/33) 0% (0/8)
7 7% (1/14) 0% (0/8)
8 75% (3/4) 0% (0/8)
Colon cancer
1 11% (1/9) ND
2 11% (1/9) ND
ND, not determined.
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proliferation in vitro and in vivo, and the mutant form of Prox1
lost its function, implicating that RNA mutations, rather than
genomic mutations, could induce or alter tumor progression.
To our knowledge, this is the first demonstration of RNA
mutation of a transcriptional factor that may be involved
in oncogenesis. Although RNA mutation found in malignant
tissues may be a cause or a consequence of carcino-
genesis, mutations of the recoding process of RNA process-
ing, particularly when it targets functionally critical residues
in proteins, may be a source of diversity in disease. As an
unfortunate side effect of this diversity, aberrant RNA mu-
tation might lead to unpredicted base modifications and
might cause epigenetic instability in cancer.
We have recently reported that Prox1 negatively regu-
lates tumor progression in HCC [11]. A transient knockdown
of prox1 by siRNA significantly accelerated the growth of
HCC cell lines in vitro, and we also demonstrated that
overexpression of Prox1 resulted in suppression of cell
Figure 4. Prox1 functions as a tumor suppressor, and mutated Prox1 loses its function in vitro. (A) Cell transformation assay in Miapaca2 cells with tet-induced
wt-Prox1, mut-Prox1, and LacZ. Cells from day 21 after incubation without (left) or with (right) tet are shown. (B) Cell proliferation was suppressed significantly by
overexpression of wt-Prox1, but not of mut-Prox1. Graphs show the fold increase of cell numbers (means and SD) for 293 and Miapaca2 cells with tet-induced
wt-Prox1, mut-Prox1, and LacZ compared with control cells without tet induction.
Figure 5. Prox1, but not mut-Prox1, suppresses the growth of xenografted tumors in mice. (A) Macroscopic views reveal that Miapaca2 cells with tet-induced wt-
Prox1 grow more slowly than control tumors (left). Growth dynamics of Miapaca2 cells estimated by the formula: tumor width2  length, expressing wt-Prox1 or
LacZ (center). (n) wt-Prox1, Dox; (5) wt-Prox1, Dox+; (.) LacZ, Dox; (o) LacZ, Dox+. Tumor weight (mg) measured after the sacrifice of mice proves that Dox-
induced wt-Prox1 suppresses tumor growth (right). *P < .05. (B) Dox-induced mut-Prox1 loses the suppressive effect of Prox1 on tumorigenesis (left). Growth
dynamics of Miapaca2 cells with Dox-induced mut-Prox1 shows loss of the suppressive function of tumor formation (center). (n) wt-Prox1, Dox; (5) wt-Prox1,
Dox+; (E) mut-Prox1, Dox; (4) mut-Prox1, Dox+. Tumor weight (mg) shows that mut-Prox1 loses the suppressive function of tumor formation (right). *P < .05.
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proliferation. Clinically, a lower expression level of Prox1
corresponded to poorer differentiation of HCC and to poor
prognosis for patients with HCC. In this study, we have
demonstrated that Prox1 overexpression using tet-on system
conferred a slower growth phenotype to pancreatic cancer
cell lines and enabled them to form much smaller tumors in
nude mice. Expression of Prox1 is downregulated in human
pancreatic cancer and correlates with its differentiation.
These data support novel functions for Prox1 as a tumor
suppressor or as a factor to regulate the progression of the
malignant character of cancer cells.
Drosophila neuroblasts divide asymmetrically to produce
differentiated cells as a result of the asymmetrical localization
of cell fate determinants and cortical cell polarity determi-
nants, including the Prox1 homologue prospero, as well as
Numb, Partner of Inscuteable (PINS), and aPKC [13]. It is
known that the disruption of the machinery regulating asym-
metrical cell division in neuroblasts leads to symmetrical cell
division and, consequently, to tumor formation. Cells lacking
PINS, Numb, or prospero are tumorigenic, and neuron-
specific expression of a constitutive active variant of aPKC
causes an increase in dividing neuroblasts [14]. Consistent
with the tumorigenic potential in Drosophila, aPKC has been
identified as a tumor suppressor in human lung cancers [15].
In fact, these molecules could protect against tumorigenesis
throughmechanisms independent of their roles in cell polarity
in humans. Although it is not known whether Prox1 regulates
asymmetrical division by stem cells in the liver or in the
pancreas, it is intriguing that Prox1 has been also identified
as a tumor suppressor in human cancers.
Posttranscriptional RNA editing is a process by which the
nucleotide sequence of a nuclear mRNA is changed from that
encoded in genomic DNA. RNA editing occurs through base
modification, by deamination of cytidine (C) to uridine (U) or
by deamination of adenosine (A) to inosine (I), in nuclear
mRNA. Uridine and inosine are recognized by translational
apparatus as thymidine and guanosine, respectively, so the
net effects are changes of C-to-T and A-to-G. A-to-I RNA
editing is mediated by members of the ADAR (adenosine
deaminases acting on RNA) family [16]. Until recently, only a
limited number of human editing substrates with an editing
site in coding regions were known, including brain-specific
glutamate receptor and G-protein–coupled serotonin re-
ceptors (5-HT2CR) [17]. Abundant A-to-I changes in mRNA
prompted us to validate prox1 as a potential substrate of
A-to-I RNA editing. We investigated whether prox1 could be
a new target for ADARs, but there was no relationship
between ADAR1 or ADAR2 expression and A-to-I mutations
for prox1 gene in cancer cell lines (unpublished data). Aux-
iliary protein may be needed for supporting the full activity
of ADARs. Alternatively, a different machinery may be re-
sponsible for A-to-I RNAmutation of the prox1 gene because
the cluster of editing sites lacks Alu repeats, where A-to-I
editing in humans has been known primarily to occur. Indeed,
a recent report suggests that the transcription repressor gene
PRDM1 is a target of RNAmutation, but the type of nucleotide
conversions (G!A, U!A) identified in their studies does
not involve the deamination process involved in A-to-I con-
versions mediated by ADARs [18]. Another example of G!A
RNA mutation has been reported in hnRNP K protein mRNA
in colorectal adenocarcinoma, and the mechanism of RNA
mutation is believed to be carried out by yet unknown factors
[19]. In human immunovirus-1 mRNA, which undergoes
G!A mutation isolated from chronically infected H9 cells,
no consensus was detected in the sequence surrounding
mutation sites, and there were no consistent secondary
structures evident in these regions [20].
Evidence of RNA editing as a potential oncogenic principle
has come from limited tumor types, such as malignant neuro-
fibromas in neurofibromatosis type I (NF1) andWilms tumors
[21]. C-to-U RNA editing of the tumor-suppressor NF1 gene
and of the Wilms tumor susceptibility gene WT1 was found
in tumor samples of patients. A-to-I RNA hyperediting of
the hematopoietic cell phosphatase (PTPH6) gene in acute
myeloid leukemiamay contribute to the decrease inwt protein
levels, suggesting its involvement in leukemogenesis [22]. In
transgenic animals of APOBEC-1, the catalytic subunit of
the apoB mRNA editing enzyme complex, the hepatic over-
expression of APOBEC-1 mediated by the promoter of apo-
lipoprotein E causes hepatocellular dysplasia and carcinoma
[23]. NAT1 (novel APOBEC-1 target 1), whose hyperediting
was identified in APOBEC-1 transgenic animals, was postu-
lated to contribute to oncogenesis [24]. However, RNA editing
of NAT1 mRNA or NF1 has not yet been identified in any
natural human carcinoma [25].
In conclusion, the finding of RNA mutation in prox1 may
challenge the currently accepted model of carcinogenesis
requiring mutations in DNA. RNA editing (of which cellular
mechanisms are currently being discovered) or RNA muta-
tion could be an important prerequisite for potential deregu-
lation during cancer development. Because the genome is
intact, RNA mutations may be repaired if the mechanisms
underlying mutation are identified, and this report would
greatly contribute to the provision of new drugs and novel
therapies for cancer patients.
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